Gastric Cancer
Conditions
Keywords
Cadonilimab, CapeOX, First-line treatment, GC/GEJC, TMEscore
Brief summary
This is a single-arm, open-label, multi-center clinical study to evaluate the efficacy and safety of PD-1/CTLA-4 bispecific cadonilimab in combination with oxaliplatin/capecitabine (CapeOX) in the first-line treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma with a high tumor microenvironment score (TMEscore). The study plans to enroll 50 patients to receive cadonilimab 100mg/kg, iv, q3w + CapeOX (oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, D1-14, q3w, with 3 weeks as a cycle and a maximum of 8 cycles of treatment. Then the maintenance treatment phase with cadonilimab ± capecitabine is entered, and the specific dosage is the same as the treatment period. Effectiveness is assessed every 9 weeks (±7 days) using RECISIT 1.1 until disease recurrence, metastasis, death, or loss of follow-up. The primary endpoint of this study was PFS, and secondary endpoints were OS, ORR, and safety.
Interventions
DRUGCadonilimab plus CapeOX chemotherapy
Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Patients voluntarily participate in the study, sign the informed consent form, and have good compliance; 2. Age≥ 18 years old, gender is not limited; 3. Histologically confirmed locally advanced unresectable or advanced metastatic adenocarcinoma of the stomach and gastroesophageal junction; 4. The tumor tissue was tested by the tumor microenvironment in the laboratory of the Department of Oncology, Nanfang Hospital, Southern Medical University, and was defined as a high tumor microenvironment score (TMEscore). 5. Her2 negative or ambiguous; 6. No prior systemic first-line therapy; 7. Subjects who have received prior adjuvant chemotherapy or neoadjuvant chemotherapy with curative intent or definitive chemo-radiotherapy for advanced disease are eligible if progression occurs \>6 months after the previous treatment; 8. ECOG physical condition 0 or 1 point; 9. Expected survival ≥ 3 months; 10. Blood tests (without transfusion within 14 days) 1) Absolute neutrophil ≥1.5×109/L, platelet ≥100×109/L, hemoglobin ≥90g/L); 2) Liver function tests (aspartate aminotransferase and glutamate aminotransferase ≤3× ULN, bilirubin ≤1.5×ULN; in case of liver metastases, AST and ALT ≤5×ULN); 3) renal function (serum creatinine ≤ 1.5×ULN, or creatinine clearance (CCr) ≥60ml/min); 11. Men and women of childbearing age must use effective contraception
Exclusion criteria
1. Squamous cell carcinoma, undifferentiated or other non-adenocarcinoma histologic type of gastric cancer or gastro-esophageal tumor; 2. Subjects with known contraindications to cadonilimab, CapeOX (see package inserts for cadonilimab, oxaliplatin, and capecitabine); 3. Known history of severe intolerance to cadonilimab, oxaliplatin, or capecitabine (i.e., grade 4 toxicity of one of the agents; grade 3-4 toxicity of other concomitant agents is not excluded); 4. Known history of hypersensitivity or hypersensitivity to cadonilimab, oxaliplatin, other platinum compounds, or fluorouracil; 5. Known brain or meningeal metastases: 6. Radiotherapy or any anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, radio-frequency ablation, traditional Chinese medicine with anti-tumor indications, immunomodulators or tumor embolization, etc.) within 4 weeks prior to the first dose of study treatment; 7. Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies, or any other antibody or drug therapy against T cell co-stimulation or checkpoint pathways; 8. Patients have had other malignancies within the past 5 years or at the same time (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix); 9. There are obvious clinical bleeding symptoms or obvious bleeding tendency, hemoptysis, etc. within 3 months before treatment. or venous/venous thrombotic event treatment within the preceding 6 months, such as cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; or requiring long-term anticoagulation with warfarin or heparin, or requiring long-term antiplatelet therapy (aspirin≥ 300 mg/day or clopidogrel ≥75 mg/day); 10. Active heart disease, including myocardial infarction, severe/unstable angina, 6 months prior to treatment. Echocardiography of left ventricular ejection fraction \<50%; 11. Known history of primary or secondary immunodeficiency virus infection 12. Concomitant active or uncontrolled severe infection 13. Any other disease, clinically significant metabolic abnormality, physical examination abnormality, or laboratory abnormality that, in the judgment of the investigator, has reason to suspect that the patient has a certain disease or state that is not suitable for the use of the study drug; 14. Any condition that, in the opinion of the investigator, may put subjects treated with study drug at risk, interfere with the study drug, subject safety assessment, or interpretation of results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | 3 years | Defined as the time between the onset of PD or death when a patient first receives the study drug, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 3 years | Defined as the time between the patient's first receipt of the study drug to death. |
| Objective Response Rate (ORR) | 3 years | Defined as the proportion of patients who achieved complete response (CR) or partial response (PR). |
| Safety | 3 years | The occurrence of various AEs, including SAEs, will be monitored based on changes in various indicators such as vital signs, physical examination, 12-lead electrocardiogram (ECG), laboratory tests, etc. AEs will be graded for severity according to NCI CTCAE 5.0. |
Countries
China
Outcome results
None listed